Search research articles
Contact Us
Filters
Showing results (231-240 of 348) with videos related to
Page
of 35
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 27, 2022
Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene
Nathalie Majeau, Annabelle Fortin-Archambault, Catherine Gérard, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 26, 2017
From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method
Benjamin Duchêne, Jean-Paul Iyombe-Engembe, Joël Rousseau, et al.
Experimental Cell Research
|
July 18, 2000
In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity
E El Fahime, Y Torrente, N J Caron, et al.
Transplantation
|
February 15, 1995
Successful myoblast allotransplantation in mdx mice using rapamycin
J T Vilquin, I Asselin, B Guérette, et al.
Human Gene Therapy
|
June 18, 2010
Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles
Christophe Pichavant, Pierre Chapdelaine, Daniel G Cerri, et al.
Transplantation Proceedings
|
February 1, 1993
Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible
R Roy, J P Tremblay, J Huard, et al.
Muscle & Nerve
|
December 1, 1994
Very efficient myoblast allotransplantation in mice under FK506 immunosuppression
I Kinoshita, J T Vilquin, B Guérette, et al.
Biotechniques
|
July 16, 2005
Real-time imaging of myoblast transplantation using the human sodium iodide symporter
Manaf Bouchentouf, Basma F Benabdallah, Marcel Dumont, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 5, 2010
Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy
Sébastien Goudenege, Yann Lamarre, Nicolas Dumont, et al.
Neurology
|
November 4, 2006
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease
P S Aisen, D Saumier, R Briand, et al.
Page
of 35
Search research articles
Search
Showing results (231-240 of 348) with videos related to
Sort By:
Page
of 35
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 27, 2022
Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene
Nathalie Majeau, Annabelle Fortin-Archambault, Catherine Gérard, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 26, 2017
From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method
Benjamin Duchêne, Jean-Paul Iyombe-Engembe, Joël Rousseau, et al.
Experimental Cell Research
|
July 18, 2000
In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity
E El Fahime, Y Torrente, N J Caron, et al.
Transplantation
|
February 15, 1995
Successful myoblast allotransplantation in mdx mice using rapamycin
J T Vilquin, I Asselin, B Guérette, et al.
Human Gene Therapy
|
June 18, 2010
Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles
Christophe Pichavant, Pierre Chapdelaine, Daniel G Cerri, et al.
Transplantation Proceedings
|
February 1, 1993
Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible
R Roy, J P Tremblay, J Huard, et al.
Muscle & Nerve
|
December 1, 1994
Very efficient myoblast allotransplantation in mice under FK506 immunosuppression
I Kinoshita, J T Vilquin, B Guérette, et al.
Biotechniques
|
July 16, 2005
Real-time imaging of myoblast transplantation using the human sodium iodide symporter
Manaf Bouchentouf, Basma F Benabdallah, Marcel Dumont, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 5, 2010
Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy
Sébastien Goudenege, Yann Lamarre, Nicolas Dumont, et al.
Neurology
|
November 4, 2006
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease
P S Aisen, D Saumier, R Briand, et al.
Page
of 35